Poland· PL-100438934

Zeposia

A ozanimod product containing ozanimodum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 2 of our 19 countries.

ATC L04AA38

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedZeposiaATCL04AA38REGISTER NO.PL-100438934PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Ozanimod is registered in 2 of 19 countries.

Countries holding a registration under ATC L04AA38 (ozanimod), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 1 of them publish a price we can compare per daily dose

Ozanimod · ATC L04AA38

2 / 19 countries

  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Ozanimodum
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Poland (PL)
ATC code
L04AA38
ATC class
Ozanimod
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    07640133688220

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

852 interactions on record for ozanimod.

Graded by severity as the source publishes them — 578 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ozanimod · interactions on record

852 records

  • 578 severe
  • 271 moderate
  • 3 minor

Most severe, free to view

  • FamotidineA02BA03severe
  • PapaverineA03AD01severe
  • IsomethepteneA03AX10severe
  • CisaprideA03FA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ozanimod in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ozanimod products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Zeposia
  • Liechtenstein · Zeposia
  • Norway · Zeposia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6f60ba15-a3a2-4685-9959-ccbf5b34fae1
GET /v1/drugs/6f60ba15-a3a2-4685-9959-ccbf5b34fae1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "0,23 mg; 0,46 mg",
  "packaging": "07640133688220 ¦ Rpz ¦ EU/1/20/1442/001 ¦ 137068\n4 kaps. 0,23 mg ¦ 3 kaps. 0,46 mg",
  "substance": "Ozanimodi hydrochloridum 0,23 mg; 0,46 mg",
  "common_name": "Ozanimodum",
  "pl_product_id": "100438934",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about ozanimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.